A Six-Week, Double-Blind, Placebo-Controlled, Randomized- Withdrawal, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Obstructive Sleep Apnea (OSA)

Trial Profile

A Six-Week, Double-Blind, Placebo-Controlled, Randomized- Withdrawal, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Obstructive Sleep Apnea (OSA)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs JZP 110 (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms TONES 4
  • Sponsors Jazz Pharmaceuticals plc
  • Most Recent Events

    • 06 Jun 2017 Results from this trial published in a Jazz Pharmaceuticals Media Release.
    • 06 Jun 2017 According to a Jazz PHarmaceuticals media release, were presented at the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) in June 2017.
    • 26 Apr 2017 According to a Jazz Pharmaceuticals media release, the results of this trial will be included in the NDA submission for JZP-110 for excessive sleepiness in obstructive sleep apnea and narcolepsy planned for late 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top